2023 World Conference on Lung Cancer (Posters)-EP07.01. A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer

EP07.01. A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the diagnostic efficiency and the impact on recurrence of performing an intraoperative needle biopsy (INB) on preoperatively undiagnosed stage 1 lung cancer. The study included 240 cases of patients who underwent radical lobectomy for lung cancer between 2012 and 2017. The diagnostic rate of INB using a 22 to 23G needle was 89.0%, and no INB-related complications were observed. The study found no significant difference in recurrence rates between the INB group and the non-INB group. Furthermore, the site of recurrence (pleural dissemination, mediastinal, other lung lobe metastases, or distant recurrence) was also not significantly different between the two groups. Cox regression analysis indicated that pleural invasion, lymphatic invasion, and vascular invasion were associated with recurrence, but performing an INB did not affect recurrence rates. The 5-year relapse-free survival rate was also similar between the two groups. The study concluded that performing an INB with a 22 to 23G needle is a safe and useful technique for diagnosing preoperatively undiagnosed stage 1 lung cancer without increasing the risk of recurrence. This finding challenges the controversy surrounding the impact of INB on recurrence and suggests that INB can be a valuable tool in guiding surgical approaches for lung resection surgery in cases with undiagnosed lung lesions.

Asset Subtitle

Yoshito Imamura

Meta Tag

Speaker Yoshito Imamura

Topic Early-Stage NSCLC: Best Practice

Keywords

study

diagnostic efficiency

recurrence

intraoperative needle biopsy

INB

stage 1 lung cancer

radical lobectomy

complications

pleural invasion

lymphatic invasion